# Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia

> **NCT02047149** · PHASE1 · TERMINATED · sponsor: **University of Massachusetts, Worcester** · enrollment: 2 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Zileuton (Zyflo®) Dasatinib (Sprycel®)
- **DRUG:** Dosing with Zileuton/Dasatinib in CML
- **DRUG:** Daily dosing of Zileuton/Dasatinib
- **DRUG:** Daily dosing with Zileuton/Dasatinib for CML

## Key facts

- **NCT ID:** NCT02047149
- **Lead sponsor:** University of Massachusetts, Worcester
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2016-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047149, "Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02047149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*